Drugs / ANX-042
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01638104 | Aug → Dec 2012 | — | Mayo Clinic | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03019653 Comparator | Jan 2017 → Sep 2024 | cardio-renal syndrome, impaired renal function disease | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANX-042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01638104 ↗ |
| Known as | Asbnp.1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594397 ↗ |
| Known as | Bnp.1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594397 ↗ |
| Modality | Peptide | “Novel Renal-Specific Peptide, ANX-042” NCT03019653 ↗ |
| Route | Intravenous | “administered by 12 hour continuous intravenous infusion” NCT01638104 ↗ |